%0 Journal Article
%T Alemtuzumab Pre-Conditioning With Tacrolimus Monotherapy in Pediatric Renal Transplantation
%A Ron Shapiro
%A Demetrius Ellis
%A Henkie P. Tan
%A Michael L. Moritz
%A Antik Basu
%A Abhay N. Vats
%A Liise K. Kayler
%A Elif Erkan
%A Corde G. McFeaters
%A Gerri Jamesd
%A Marr J. Grosso
%A Adriana Zeevi
%A Edward A. Gray
%A Amadeo Marcos
%A and Thomas E. Starzl
%J American Journal of Transplantation
%P 2736-2738
%@ 1600-6143
%D 2007
%R 10.1111/j.1600-6143.2007.01987.x
%X We employed antibody pre-conditioning with alemtuzumab and posttransplant immunosuppression with low-dose tacrolimus monotherapy in 26 consecutive pediatric kidney transplant recipients between January 2004 and December 2005. Mean recipient age was 10.7 ¡À 5.8 years, 7.7% were undergoing retransplantation, and 3.8% were sensitized, with a PRA >20%. Mean donor age was 32.8 ¡À 9.2 years. Living donors were utilized in 65% of the transplants. Mean cold ischemia time was 27.6 ¡À 6.4 h. The mean number of HLA mismatches was 3.3 ¡À 1.3. Mean follow-up was 25 ¡À 8 months. One and 2 year patient survival was 100% and 96%. One and 2 year graft survival was 96% and 88%. Mean serum creatinine was 1.1 ¡À 0.6 mg/dL, and calculated creatinine clearance was 82.3
¡À 29.4 mL/min/1.73 m2. The incidence of pre-weaning acute rejection was 11.5%; the incidence of delayed graft function was 7.7%. Eighteen (69%) of the children were tapered to spaced tacrolimus monotherapy, 10.5 ¡À 2.2 months after transplantation. The incidence of CMV, PTLD and BK virus was 0%; the incidence of posttransplant diabetes was 7.7%. Although more follow-up is clearly needed, antibody pre-conditioning with alemtuzumab and tacrolimus monotherapy may be a safe and effective regimen in pediatric renal transplantation.
%K Immunosuppression
%K kidney transplantation
%K pediatric
%U http://onlinelibrary.wiley.com/doi/10.1111/j.1600-6143.2007.01987.x/abstract